SAM Nordic are happy to announce that the kit TEKTROTYD has received Marketing Authorisation in Sweden, Finland, Norway and Denmark this day.
99mTc-Tektrotyd is a radiopharmaceutical indicated for diagnostics of pathological lesions in which somatostatin receptors are overexpressed (particularly subtype 2 and, to a lesser extent, subtypes 3 and 5) and which may be imaged by the labelled ligand.
In particular, these are:
- Gastro-entero-pancreatic neuroendocrine tumours (GEP-NET);
- pituitary adenomas;
- tumours originating in a sympathetic system; pheochromocytoma, paraganglioma, neuroblastoma, ganglioneurinoma etc.;
- medullary thyroid carcinoma;
- the preparation may be potentially useful in the case of other tumours expressing somatostatin receptors of various intensity. Other tumours which may overexpress somatostatin receptors: breast cancer, melanoma, lymphomas, prostate cancer, NSCLC, sarcoma, renal cell carcinoma, differentiated thyroid carcinoma, astrocytoma according to WHO I-IV (including glioblastoma multiforme G-M), meningiomas, ovarian cancer.
Share
